BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ArthroSurface Performs First Biological Knee Procedure


12/17/2010 10:26:14 AM

FRANKLIN, Mass., Dec. 17, 2010 /PRNewswire/ -- Arthrosurface, Inc. (www.arthrosurface.com), the developer of less-invasive joint resurfacing systems, announced that it has performed its first biological knee procedure based on the company's proven HemiCAP® platform technology.

The next generation HemiCAP(BIO) implant is providing a biological scaffold with a cell-friendly surface environment that is supported by a stable, contoured implant.

Arthroscopic cartilage procedures have been targeting bone marrow cells for focal cartilage repair for over two decades. "We are excited to combine our focal HemiCAP® resurfacing technology with the cellular healing response achieved by bone marrow influx," commented Steven Ek, COO.

The technology provides a load sharing matrix that has shown to provide complete biological surface coverage in preclinical tests, said Matthias Schurhoff, MD, VP of Clinical Operations and Scientific Affairs.

Dr. Willem van der Merwe, Sport Science Centre of South Africa, performed the first bio HemiCAP® surgery and has more than five years of experience with the classic HemiCAP® procedure: "I am very satisfied with the follow-up on my previous patients and observed a remarkable return to sports activities. Now, we look forward to assessing the clinical performance criteria for the new bio surface."

The HemiCAP® implant for the femoral condyle is targeting middle aged patients with weight bearing full thickness defects who continue to suffer from knee pain.

Joint preservation is critical for the long term management of knee arthritis. Focal HemiCAP® resurfacing expands reconstructive treatment options intended to delay traditional arthroplasty for patients. In contrast to conventional joint replacement, the company's resurfacing technology allows the surgeon to precisely mill the surface to cover the defect and fit the implant to the patient while preserving healthy cartilage, bone, and soft tissues.

"Arthrosurface continuous to grow its platform to address early and late stage knee arthritis," said Steven Tallarida, President, who observed the first HemiCAP(BIO) implantation.

The system currently offers over 140 different sizes and shapes to effectively treat cartilage defects in a large variety of joints by recreating the patient's joint geometry with an intraoperative 3-D mapping system.

SOURCE Arthrosurface, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES